You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.
Are you sure you want to leave?
Cancel
Complete the Medscape Education module, ‘Focus on SHPT: new approaches for better mineral homeostasis through vitamin D sufficiency’
The module is intended for an international audience of non-US nephrologists, primary care physicians and diabetologists/endocrinologists, particularly those in Europe. As it has expired, you will not earn any continuing professional development (CPD) credits upon completing it. However, it still offers a wide range of useful and valid insights from which you can benefit.
What will you learn?
Authored by professors Jordi Bover,* Marcus Ketteler,† Marc G Vervloet‡ and James B Wetmore,§ this educational module is designed to enhance your awareness of new approaches to establishing vitamin D sufficiency and how they improve the management of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD).
Available on Medscape Education, the module consists of an expert article and a series of short presentations, the slides for which are available for download.
If you complete the module, you will improve your awareness and understanding of:
- SHPT and its treatment in stage 3 or 4 CKD patients
- The latest clinical data on new methods of establishing vitamin D sufficiency
- Evidence-based SHPT treatment guidelines
The module is also designed to help you improve your competence in:
- Assessing and diagnosing SHPT in patients with stage 3 or 4 CKD early
- Interpreting SHPT treatment guidelines
- Developing individualised treatment plans for SHPT patients with the goal of achieving better morbidity and mortality outcomes
Released on 22 May 2020, the module expired on 22 May 2021 but remains available for all to benefit.
Footnotes
*Clinical Professor of Nephrology; Fundació Puigvert, Universitat Autònoma de Barcelona; Barcelona, Spain.
†Professor of Medicine; Robert-Bosch-Krankenhaus; Stuttgart, Germany.
‡Professor of Nephrology; Amsterdam University Medical Center; Amsterdam, The Netherlands.
§Professor of Medicine; University of Minnesota School of Medicine; Minneapolis, Minnesota, USA.
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. The Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma, a joint company with Fresenius Medical Care. For more information about Vifor Pharma, please visit www.viforpharma.com
This site does not provide medical advice and may not be relied upon by any healthcare practitioner in exercising his or her professional judgement in the practice of medicine. The information provided herein is provided for general educational purposes only, and is not to be used or relied on for any diagnostic or treatment purposes. This material is not intended to represent the best or only methods or procedures appropriate for the medical situations discussed; rather the material is intended to present an approach, view, statement or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. VFMCRP makes no warranties or representations as to the site's accuracy, completeness or up-to-date information. All users agree that access to this site is at their own risk, and that neither VFMCRP any party involved in creating or delivering this site shall be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if VFMCRP has been advised of the possibility of such damages) arising out of access to, or use of the information contained on this site, or any errors or omissions, misprints, out-of-date information, technical or pricing inaccuracies, typographical or other errors appearing on this site. This limitation includes damages to, or for any viruses that may infect your computer equipment.
© 2021 Vifor Fresenius Medical Care Renal Pharma
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd., a company of the Vifor Pharma Group, is the partner of choice for renal pharmaceutical and innovative, patient-focused solutions. The Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology …
Read More
